George Demetri, MD
Enriched profileSenior Vice President for Experimental Therapeutics; Director, Center for Sarcoma and Bone Oncology; Quick Family Chair in Medical Oncology, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute; Professor of Medicine
George Demetri is Senior Vice President for Experimental Therapeutics; Director, Center for Sarcoma and Bone Oncology; Quick Family Chair in Medical Oncology, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute; Professor of Medicine. OpenAlex indexes 637 publications with 64,250 citations (h-index 115); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
George Demetri, MD, is Senior Vice President for Experimental Therapeutics at Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School. The public record shows 637 publications with 64,250 citations (h-index 115), centered on Sarcoma Diagnosis and Treatment, Gastrointestinal Tumor Research and Treatment, Lung Cancer Treatments and Mutations. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 15 companies, 1 NIH-funded awards (2007–2011).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Sarcoma Diagnosis and Treatment
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 15 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 297.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib
Sponsor: Infinity Pharmaceuticals, Inc.
- Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
Sponsor: Infinity Pharmaceuticals, Inc.
- S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 14 Oct 2026
15 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Aadi Bioscience, Inc.Program year20252 payments$20,000openpaymentsdata.cms.gov ↗
- Blueprint Medicines CorporationProgram year20253 payments$15,000openpaymentsdata.cms.gov ↗
- Merck KGaAProgram year20253 payments$10,075openpaymentsdata.cms.gov ↗
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2007–2011 per NIH RePORTER. The latest:
- Targeted Therapy Resistance Mechanisms in Gastrointestinal Stromal Tumor(GIST)
Dana-Farber Cancer Inst
FY2011$194,934P50CA127003 - Targeted Therapy Resistance Mechanisms in Gastrointestinal Stromal Tumor(GIST)
Dana-Farber Cancer Inst
FY2010$214,952P50CA127003 - Targeted Therapy Resistance Mechanisms in Gastrointestinal Stromal Tumor(GIST)
Dana-Farber Cancer Inst
FY2009$212,997P50CA127003
Congress activity
Updated 14 Oct 2026
105 congress contributions (2004–2025) across AACR, ASCO, ESMO per OpenAlex. The most recent:
- Abstract 1180: Epigenetic dysregulation of IGF1 and PPARG2 in dedifferentiated liposarcoma
AACR Annual Meeting
AACR2025Co-author - Abstract 6941: Preclinical efficacy of the CK1 alpha/CDK7/CDK9 inhibitor BTX-A51 in <i>CIC</i>-rearranged sarcoma
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma.
Clinical cancer research
Clinical Trial2026 - Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.
Nature communications
Clinical Trial2026 - Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.
Science translational medicine
Article2026 - Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.
Clinical cancer research
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)- 01Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsArticle4,406 citations2002
- 02
- 03Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorArticle2,300 citations2003
- 04<i>PDGFRA</i> Activating Mutations in Gastrointestinal Stromal TumorsArticle2,300 citations2003
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/george-demetri-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- X / Twitter
x.com/ASCO/status/1292086423173173249
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - X / Twitter
X/Twitter handle @DrSarcoma referenced by ASCO's official account covering his Karnofsky Award lecture
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- MD
Stanford University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Editorial Board
The ASCO Post
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Board of Directors
Connective Tissue Oncology Society; Medical Advisory Board, Sarcoma Foundation of America
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →curesarcoma.org ↗ - Director
Ludwig Center at Harvard; Executive Director for Clinical and Translational Research, Ludwig Institute for Cancer Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- David A. Karnofsky Memorial Award
American Society of Clinical Oncology (2020), for pioneering targeted kinase inhibitors (imatinib, sunitinib, regorafenib) for GIST and sarcomas
2020verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dailynews.ascopubs.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- Board Member
Blueprint Medicines Corp.
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ir.blueprintmedicines.com ↗ - Board of Directors
G1 Therapeutics, Inc.
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →g1therapeutics.com ↗ - Clinical/Scientific Advisor
Bessor Pharma
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bessorpharma.com ↗
Media & interviews
press, podcasts and appearances- Video: "Dr. George Demetri Discusses Liposarcoma"
Dana-Farber Cancer Institute Health Library
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pbs.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Richard Gorlick, MD
The University of Texas MD Anderson Cancer Center
William Tap, MD
Memorial Sloan Kettering Cancer Center
Scott Schuetze, MD
University of Michigan Medical School
Steven Dubois, MD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Harvard Medical School